Patient demographics and clinical characteristics (N = 44)
| . | n (%) . |
|---|---|
| Age, y | |
| Median | 34.5 |
| Range | 18-75 |
| Sex | |
| Male | 29 (66) |
| Female | 15 (34) |
| Race | |
| African American | 2 (4.5) |
| Hispanic | 29 (66) |
| White | 8 (18) |
| Other | 5 (11) |
| Sample collection | |
| Pretreatment only | 28 |
| Pretreatment/posttreatment | 10 |
| Posttreatment only | 6 |
| WBC count, ×109/L | |
| Median | 3 |
| Range | 0.1-21 |
| Salvage treatment phase | |
| First | 14 (32) |
| Second | 11 (25) |
| Third | 12 (27) |
| Fourth | 6 (14) |
| Fifth | 1 (2) |
| BM blast percentage, % | |
| Median | 80 |
| Range | 0.2-100 |
| <5 | 1 (2.3) |
| ≥5 to ≤50 | 13 (30) |
| >50 | 25 (57) |
| Unknown | 5 (11) |
| Cytogenetics | |
| Standard risk | 36 (82) |
| High risk (Ph+, hypodiploid) | 8 (18) |
| CD19 expression on leukemic blasts | |
| Weak/diminished | 5 (14) |
| Strong | 32 (86) |
| . | n (%) . |
|---|---|
| Age, y | |
| Median | 34.5 |
| Range | 18-75 |
| Sex | |
| Male | 29 (66) |
| Female | 15 (34) |
| Race | |
| African American | 2 (4.5) |
| Hispanic | 29 (66) |
| White | 8 (18) |
| Other | 5 (11) |
| Sample collection | |
| Pretreatment only | 28 |
| Pretreatment/posttreatment | 10 |
| Posttreatment only | 6 |
| WBC count, ×109/L | |
| Median | 3 |
| Range | 0.1-21 |
| Salvage treatment phase | |
| First | 14 (32) |
| Second | 11 (25) |
| Third | 12 (27) |
| Fourth | 6 (14) |
| Fifth | 1 (2) |
| BM blast percentage, % | |
| Median | 80 |
| Range | 0.2-100 |
| <5 | 1 (2.3) |
| ≥5 to ≤50 | 13 (30) |
| >50 | 25 (57) |
| Unknown | 5 (11) |
| Cytogenetics | |
| Standard risk | 36 (82) |
| High risk (Ph+, hypodiploid) | 8 (18) |
| CD19 expression on leukemic blasts | |
| Weak/diminished | 5 (14) |
| Strong | 32 (86) |
BM, bone marrow; WBC, white blood cell.